CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $205.07M, lower than 95% of all stocks globally
- PositionGross margin is -59.7%, lower than 95% of its Biotechnology peers (median 67.1%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
289.63BKRW205.07M · vs all stocks (USD)
Revenue (TTM)
353.53MKRW250.32K · vs all stocks (USD)
Beta
2.25xvs all stocks
52-Week Change
-29.04%vs all stocks
Market Capitalization
289.63BKRW205.07M · vs all stocks (USD)
Enterprise Value
248.28BKRW175.79M · vs all stocks (USD)
Price to Book (MRQ)
2.32xvs Biotechnology peers
Enterprise to Revenue
702.27xvs Biotechnology peers
Enterprise to EBITDA
-56.98xvs Biotechnology peers
Gross Margin
-59.75%vs Biotechnology peers
Operating Margin
-793.93%vs Biotechnology peers
Return on Assets (TTM)
-7.44%vs Biotechnology peers
Return on Equity (TTM)
-7.79%vs Biotechnology peers
Revenue (TTM)
353.53MKRW250.32K · vs all stocks (USD)
Revenue per Share (TTM)
16.89KRWUpdated Aug 19, 2026Quarterly Revenue Growth
20.60%vs Biotechnology peers
Gross Profit (TTM)
-404.69MKRW-286.54K · vs all stocks (USD)
EBITDA (TTM)
-4.36BKRW-3.08M · vs all stocks (USD)
Net Income (TTM)
-7.39BKRW-5.23M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
20.58%vs Biotechnology peers
Operating Cash Flow (TTM)
-2.31BKRW-1.63M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-8.99BKRW-6.36M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
239.96MKRWFY2025 · Dec 31, 2025Revenue
3.76BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
3.05BKRWFY2025 · Dec 31, 2025Gross Profit
713.90MKRWFY2025 · Dec 31, 2025Operating Income
-11.30BKRW-8.00M · vs all stocks (USD)
Pre-tax Income
-9.11BKRWFY2025 · Dec 31, 2025Income Tax Expense
11.47MKRWFY2025 · Dec 31, 2025Net Income
-9.13BKRWFY2025 · Dec 31, 2025EBIT
-8.78BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-7.20BKRWFY2025 · Dec 31, 2025Research & Development
3.79BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
1.81BKRWFY2025 · Dec 31, 2025Other Operating Expenses
426.49MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
2.03BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
338.07MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-9.13BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
139.32MKRWFY2025 · Dec 31, 2025Operating Cash Flow
-10.66BKRWFY2025 · Dec 31, 2025Free Cash Flow
-13.35BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
16.31BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-9.13BKRWFY2025 · Dec 31, 2025Stock-based Compensation
991.55MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-1.85BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-74.02MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-609.26MKRWFY2025 · Dec 31, 2025Capital Expenditures
-2.68BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-19.36MKRWFY2025 · Dec 31, 2025Purchase of Investments
-8.07BKRWFY2025 · Dec 31, 2025Sale of Investments
7.68BKRWFY2025 · Dec 31, 2025Other Investing Activity
161.68MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.92BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
231.96MKRWFY2025 · Dec 31, 2025Shares Outstanding
24.53MSharesUpdated Aug 19, 2026Float Shares
13.91MSharesUpdated Aug 19, 2026% Held by Insiders
16.84%vs all stocks
% Held by Institutions
0.35%vs all stocks
Total Cash (MRQ)
75.39BKRW53.38M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.10KKRWUpdated Aug 19, 2026Total Debt (MRQ)
55.19MKRW39.07K · vs all stocks (USD)
Current Ratio (MRQ)
126.75xvs Biotechnology peers
Book Value per Share (MRQ)
5.08KKRWUpdated Aug 19, 2026Total Assets
120.76BKRW85.50M · vs all stocks (USD)
Total Current Assets
78.91BKRWFY2025 · Dec 31, 2025Total Liabilities
5.45BKRWFY2025 · Dec 31, 2025Total Non-current Assets
41.86BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
1.01BKRWFY2025 · Dec 31, 2025Total Current Liabilities
4.44BKRWFY2025 · Dec 31, 2025Cash Equivalents
16.31BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
16.31BKRWFY2025 · Dec 31, 2025Other Short-term Investments
61.05BKRWFY2025 · Dec 31, 2025Accounts Receivable
384.04MKRWFY2025 · Dec 31, 2025Inventory
265.30MKRWFY2025 · Dec 31, 2025Accounts Payable
76.89MKRWFY2025 · Dec 31, 2025Short-term Debt
2.34BKRWFY2025 · Dec 31, 2025Other Current Liabilities
460.00KRWFY2025 · Dec 31, 2025Long-term Debt
24.81MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-210.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
12.19BKRWFY2025 · Dec 31, 2025Retained Earnings
12.04BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
115.31BKRW81.64M · vs all stocks (USD)
Treasury Stock
4.71BKRWFY2025 · Dec 31, 202552-Week Low
10.01KKRWUpdated Aug 19, 202652-Week High
33.30KKRWUpdated Aug 19, 202652-Week Change
-29.04%vs all stocks
Beta
2.25xvs all stocks
50-Day MA
11.95KKRWUpdated Aug 19, 2026200-Day MA
19.15KKRWUpdated Aug 19, 2026Avg 10-Day Volume
107.56KSharesUpdated Aug 19, 2026Avg 30-Day Volume
108.71KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-374.00KRWUpdated Aug 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -59.7%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: -0.60Industry median: 0.67Industry P5: 0.14Peers compared: 261
Current ratio is 126.75×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 126.746Industry median: 5.64Industry P95: 23.02Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $205.07M, lower than 95% of all stocks globallySignificant
Market cap (USD): 205,070,291.466Global P5: 269,387,740.27
Revenue is $250,316, lower than 95% of all stocks globallySignificant
Revenue (USD): 250,316.383Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
NextBioMedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hans Biomed Corp.
Tier 1ProductionApproval-Gated PipelineRule
Avidity Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Humedix Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Keros Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Koa Shoji Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
ImmuneOncia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Suzhou Jinhong Shun Auto Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineLow-Leverage Liquidity Configuration
Beijing Labtech Instrument Co., Ltd.
2 interpretationsPartial Recovery After Sharp DeclineLow-Leverage Liquidity Configuration
Allgens Medical Technology Inc.
2 interpretationsPartial Recovery After Sharp DeclineLow-Leverage Liquidity Configuration